Events - Invivoscribe

UPCOMING EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-27T18:13:43+00:00May 15th, 2020|

VIRTUAL
May 29 – 30, 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

admin2020-05-27T18:11:58+00:00May 15th, 2020|

VIRTUAL
June 11 – 14, 2020

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-27T18:13:43+00:00May 15th, 2020|

VIRTUAL
May 29 – 30, 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

admin2020-05-27T18:11:58+00:00May 15th, 2020|

VIRTUAL
June 11 – 14, 2020

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-27T18:13:43+00:00May 15th, 2020|

VIRTUAL
May 29 – 30, 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

admin2020-05-27T18:11:58+00:00May 15th, 2020|

VIRTUAL
June 11 – 14, 2020

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-27T18:13:43+00:00May 15th, 2020|

VIRTUAL
May 29 – 30, 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

admin2020-05-27T18:11:58+00:00May 15th, 2020|

VIRTUAL
June 11 – 14, 2020

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate
drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

UPCOMING EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

PAST EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

UPCOMING EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

PAST EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 30th, 2020 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

August 13th, 2020 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

UPCOMING EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

PAST EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

UPCOMING EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

PAST EVENTS

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia